Parasites: Eviction notice served on Toxoplasma
The gene RARRES3 uses an unexpected strategy to eliminate the parasite Toxoplasma gondii from human cells.
- Department of Molecular and Cell Biology, University of California Merced, United States
- Health Science Research Institute, University of California, Merced, United States
Cells have a variety of defense mechanisms for eliminating parasites, bacteria and other pathogens. To evade eviction, some of these pathogens sequester themselves inside structures called vacuoles once they are inside the cell. This allows the pathogens to grow ‘rent-free’, scavenging food from the cytosol without triggering the many ‘trip wires’ that lie immediately beyond the vacuole.
Many parasites rely on this strategy to survive, including Toxoplasma gondii, the microorganism that causes toxoplasmosis. When T. gondii is ingested by a human or other warm-blooded animal, the parasite invades cells lining the small intestine, using the plasma membrane of the cells to form the membrane of the vacuole (Figure 1; Suss-Toby et al., 1996). Once inside, the parasite starts to divide and mature into a new form that then gets released via a process called egress; the freshly egressed parasite then seeks out new cells to invade and quickly spreads throughout the body. T. gondii is considered one of the world’s most successful parasites because, once fully developed, it can infect virtually any cell with a nucleus. So, how does the host’s immune system remove this unauthorized occupant?
Figure 1
A new way of evicting Toxoplasma gondii from cells.
In resting cells, T. gondii (green) creates a vacuole surrounded by a membrane, inside which it can replicate and grow without being destroyed by the immune system (left). However, when the immune system stimulates the cell with a protein called interferon gamma (IFNγ; right), multiple genes are activated, including a gene called RARRES3 which codes for a phospholipase enzyme and is regulated by a transcription factor called IRF1. Rinkenberger et al. show that RARRES3 restricts vacuolar growth and causes T. gondii to prematurely exit the cell.
Image credit: Figure created using BioRender.com.
Most of the immune responses against T. gondii are regulated by a protein messenger called interferon gamma (IFNγ), which causes infected cells to transcribe hundreds of genes coding for proteins that stop the parasite from replicating (Pfefferkorn et al., 1986; Suzuki et al., 1988; Schoggins, 2019). In mice, IFNγ activates two sets of genes: one set codes for immunity-related GTPases (IRGs), and the other codes for guanylate binding proteins (GBPs). These proteins surround and disrupt the vacuole membrane, thereby killing the parasite growing inside (Martens et al., 2005; Ling et al., 2006; Yamamoto et al., 2012).
It is well established that the level of damage caused by different strains of T. gondii depends on their capacity to deactivate IRGs (Hunter and Sibley, 2012). Humans, however, do not have this IRG system, and much less is known about how our bodies kill off T. gondii (Bekpen et al., 2005; Saeij and Frickel, 2017). Now, in eLife, David Sibley and colleagues from Washington University and the University of Texas Southwestern Medical Center – including Nicholas Rinkenberger as first author – report how an IFNγ-stimulated gene called RARRES3 restricts T. gondii infections in human cells (Rinkenberger et al., 2021).
First, the team used a forward genetic approach that involved individually overexpressing hundreds of IFNγ-stimulated genes to see which ones interfered with the growth and replication of T. gondii. These experiments, which were carried out on human cells cultured in the laboratory, led to the discovery of RARRES3, a gene that codes for an understudied phospholipase enzyme that plays a role in lipid metabolism (Mardian et al., 2015).
Because the parasitic vacuole cannot fuse with other compartments, the infected cell cannot dispose of T. gondii by transporting it to the cell surface or degrading it in its lysosome (Mordue et al., 1999). Therefore, most IFNγ-stimulated genes eliminate the parasite by either disrupting the membrane surrounding the vacuole or ‘blowing up’ the infected cell (Saeij and Frickel, 2017). However, Rinkenberger et al. found that RARRES3 does not trigger either of these defense mechanisms. Instead, it reduces the size of the vacuole, causing T. gondii to egress before it has fully matured (Figure 1). This mechanism was shown to be specific to RARRES3, as this effect was not observed when the activity of the enzyme encoded by the gene was inhibited. In addition, restriction of the parasite’s vacuole was found to work independently from all other pathways known to induce cell death.
So, how does the parasite receive the eviction notice served by the RARRES3 gene, and how does the phospholipase enzyme encoded by this gene shrink the vacuole? T. gondii feeds on a variety of biomolecules and scavenges lipids from lipid droplets in the cytosol of its host cell (Nolan et al., 2017). Perhaps the enzyme starves the parasite by simply metabolizing these lipids before the parasite can get to them. Or maybe it somehow stops the parasite from using these lipids to expand the membrane around the vacuole. Interestingly, RARRES3 was found to only restrict strains of T. gondii that do not cause severe disease in mice and possibly humans. This suggests that there are likely to be other unknown mechanisms that explain why some strains of T. gondii cause more dangerous effects than others.
At first glance, it may seem that removing T. gondii from the cell (without killing it) will actually help the parasite to spread; however, there are some advantages to this strategy. First, it exposes the parasite to the extracellular environment, where it will encounter other components of the immune system (Souza et al., 2021). Second, it is possible that restricting the parasite’s food intake means it cannot build all the machinery it needs to invade new cells before being prematurely evicted. Further exploration of these possibilities may provide new insights into the ways that T. gondii and other disease-causing parasites use vacuoles to protect themselves.
References
-
Modulation of innate immunity by Toxoplasma gondii virulence effectorsNature Reviews. Microbiology 10:766–778.https://doi.org/10.1038/nrmicro2858
-
Vacuolar and plasma membrane stripping and autophagic elimination of Toxoplasma gondii in primed effector macrophagesThe Journal of Experimental Medicine 203:2063–2071.https://doi.org/10.1084/jem.20061318
-
The HRASLS (PLA/AT) subfamily of enzymesJournal of Biomedical Science 22:99.https://doi.org/10.1186/s12929-015-0210-7
-
Interferon-gamma suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophanMolecular and Biochemical Parasitology 20:215–224.https://doi.org/10.1016/0166-6851(86)90101-5
-
Exposing Toxoplasma gondii hiding inside the vacuole: a role for GBPs, autophagy and host cell deathCurrent Opinion in Microbiology 40:72–80.https://doi.org/10.1016/j.mib.2017.10.021
-
Interferon-stimulated genes: what do they all do?Annual Review of Virology 6:567–584.https://doi.org/10.1146/annurev-virology-092818-015756
Article and author information
Author details
Juan C Sánchez-Arcila
Publication history
Copyright
© 2022, Sánchez-Arcila and Jensen
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,160
- views
-
- 107
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Parasites: Eviction notice served on Toxoplasma
eLife 11:e76246.
https://doi.org/10.7554/eLife.76246
Further reading
-
- Immunology and Inflammation
- Microbiology and Infectious Disease
Pseudomonas aeruginosa (PA) is an opportunistic, frequently multidrug-resistant pathogen that can cause severe infections in hospitalized patients. Antibodies against the PA virulence factor, PcrV, protect from death and disease in a variety of animal models. However, clinical trials of PcrV-binding antibody-based products have thus far failed to demonstrate benefit. Prior candidates were derivations of antibodies identified using protein-immunized animal systems and required extensive engineering to optimize binding and/or reduce immunogenicity. Of note, PA infections are common in people with cystic fibrosis (pwCF), who are generally believed to mount normal adaptive immune responses. Here, we utilized a tetramer reagent to detect and isolate PcrV-specific B cells in pwCF and, via single-cell sorting and paired-chain sequencing, identified the B cell receptor (BCR) variable region sequences that confer PcrV-specificity. We derived multiple high affinity anti-PcrV monoclonal antibodies (mAbs) from PcrV-specific B cells across three donors, including mAbs that exhibit potent anti-PA activity in a murine pneumonia model. This robust strategy for mAb discovery expands what is known about PA-specific B cells in pwCF and yields novel mAbs with potential for future clinical use.
-
- Microbiology and Infectious Disease
The persistence of latent viral reservoirs remains the major obstacle to eradicating human immunodeficiency virus (HIV). We herein found that ICP34.5 can act as an antagonistic factor for the reactivation of HIV latency by herpes simplex virus type I (HSV-1), and thus recombinant HSV-1 with ICP34.5 deletion could more effectively reactivate HIV latency than its wild-type counterpart. Mechanistically, HSV-ΔICP34.5 promoted the phosphorylation of HSF1 by decreasing the recruitment of protein phosphatase 1 (PP1α), thus effectively binding to the HIV LTR to reactivate the latent reservoirs. In addition, HSV-ΔICP34.5 enhanced the phosphorylation of IKKα/β through the degradation of IκBα, leading to p65 accumulation in the nucleus to elicit NF-κB pathway-dependent reactivation of HIV latency. Then, we constructed the recombinant HSV-ΔICP34.5 expressing simian immunodeficiency virus (SIV) env, gag, or the fusion antigen sPD1-SIVgag as a therapeutic vaccine, aiming to achieve a functional cure by simultaneously reactivating viral latency and eliciting antigen-specific immune responses. Results showed that these constructs effectively elicited SIV-specific immune responses, reactivated SIV latency, and delayed viral rebound after the interruption of antiretroviral therapy (ART) in chronically SIV-infected rhesus macaques. Collectively, these findings provide insights into the rational design of HSV-vectored therapeutic strategies for pursuing an HIV functional cure.
